A new modality

Determining the best course of treatment for cancer and autoimmune patients by analyzing internal cell signaling pathways is the goal of diagnostics company Nodality Inc., which received a $15.5 million extension of a series B round last week.

Based on science developed by Professor Garry Nolan and licensed from Stanford University, Nodality's multiparametric Single Cell Network Profiling (SCNP) technology uses quantitative flow cytometry to characterize signaling networks within individual cells...